Palvella Therapeutics (NASDAQ:PVLA) issued a comprehensive 2026 corporate update detailing significant progress across its late-stage QTORIN platform, which leverages a proprietary topical rapamycin formulation for the treatment of rare dermatological and vascular conditions.
The pivotal Phase 3 SELVA trial evaluating QTORIN rapamycin for microcystic lymphatic malformations has completed enrollment with 51 patients, exceeding the original target of 40.
Topline results are anticipated in March 2026, with a planned new drug application (NDA) submission to the U.S. Food and Drug Administration in the second half of 2026 should the data prove positive.
In the Phase 2 TOIVA study of QTORIN rapamycin in cutaneous venous malformations, positive results demonstrated a 73% improvement in lesion severity.
The company has requested a Preliminary Breakthrough Therapy Advice meeting with the FDA in the first quarter of 2026 to discuss potential expedited pathways for this indication.
Palvella also outlined plans to initiate additional Phase 2 studies and introduce a new QTORIN candidate in the second half of 2026, further expanding its pipeline targeting underserved rare skin and vascular diseases.
The company highlighted robust intellectual property protection, with composition-of-matter patents for rapamycin extending through 2038 and potential protection for pitavastatin formulations through 2046.
To support future commercialization and technical advancement, Palvella has made key leadership hires in commercial strategy and technical operations, strengthening its readiness for potential regulatory approval and market entry.
Management expressed confidence in the QTORIN platform's potential to address significant unmet needs in rare diseases, with multiple near-term catalysts expected throughout 2026.